[Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer].
Severe hepatotoxicity occurred in a prostate cancer patient treated with 375 mg of flutamide per day, 125 mg three times a day, for 11 weeks. Serial measurements of serum concentrations of flutamide and its metabolites in the patient showed an unusually high serum level and delayed elimination of flutamide and suggested decreased metabolic activity of oxidation of flutamide to OH-flutamide. In 37 patients with prostate cancer we periodically monitored the serum concentrations of flutamide as well as liver function parameters. In 2 patients, glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) elevated over 100 IU/L, and treatment with flutamide was discontinued. Slight elevation of GOT and GPT over 40 to 100 IU/L was also detected in 5 patients, and flutamide was withdrawn. The elevated GOT and GPT in these 7 patients recovered to the pretreatment levels after discontinuation of the treatment. In these patients with flutamide-induced hepatic disorders, the average serum concentration of flutamide was higher (2.76 times, and that of OH-flutamide was lower (0.76 times), as compared with patients who maintained normal liver function.
Nakagawa
Y
Y
Department of Urology, Ayabe Municipal Hospital.
Koyama
M
M
Matsumoto
M
M
D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000097:blood; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000175:diagnosis* / Q000378:metabolism; D005485:Flutamide / Q000009:adverse effects* / Q000097:blood; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D005485:Flutamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase